Nov. 25, 2022

Sysmex Corporation will present the latest data on Alzheimer's Disease diagnostics using blood at "The 15th Clinical Trials on Alzheimer's Disease (CTAD) " to be held from November 29 to December 2, 2022 in San Francisco, California, United States.

Session Subject Presenter
(Affiliation)
Poster:
Clinical Trials:
Biomarkers including plasma
（LP84A*1） 		Three group classification of participants based on fully automated plasma β-amyloid measurements to achieve high positive and negative predictive values.

Poster presentation：December 1 (Thursday) 8:00 - 18:00 （PST）

Kazuto Yamashita
（SYSMEX）
Poster:
Clinical Trials:
Biomarkers including plasma
（LP74） 		Effects of pre-analytical parameters on plasma β-amyloid level.

Poster presentation：December 1 (Thursday) 8:00 - 18:00 （PST）

Kengo Ishiki
（SYSMEX）
Poster:
Clinical Trials:
Biomarkers including plasma
（LP68*2） 		Age dependency of plasma β-amyloid measured by fully automated and highly specific immunoassays in a Japanese cohort study (SESSA).

Poster presentation：December 1 (Thursday) 8:00 - 18:00（PST）

Kengo Ishiki
（SYSMEX）
Terminology
1 Joint announcement with Sysmex Corporation, Eisai Co., Ltd., and Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology.
2 Joint announcement with Sysmex Corporation, and Shiga University of Medical Science.

  • Information contained in the topics is current as of the date of the announcement,
    but may be subject to change without prior notice.

Attachments

Disclaimer

Sysmex Corporation published this content on 25 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 November 2022 00:13:09 UTC.